A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

Dr Reddy’s sees plenty of opportunity in Europe, including for the firm’s burgeoning biosimilars business. However at the same time, current European pricing policies risk exacerbating shortages and are discouraging investment, the firm’s CEO of European operations for global generics, Patrick Aghanian, tells Generics Bulletin in an exclusive interview.

Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.